Role of infectious agents in the carcinogenesis of brain and head and neck cancers

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Alibek, Kenneth ^a,b   Kakpenova, Ainur ^a   Baiken, Yeldar ^a  

^a NAZARBAYEV UNIVERSITY   (Kazakhstan)

^b Republican Scientific Center for Emergency Care   (Kazakhstan)

Author keywords

Brain cancer; Carcinogenesis; Cytomegalovirus; Epstein Barr virus; Head and neck cancer; HIV; Human papilloma virus; Polyomavirus; Streptococcus anginosus; Toxoplasma

Indexed keywords

VIRUS PROTEIN; WART VIRUS VACCINE;

BACTERIAL INFECTION; BRAIN CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK POPULATION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MEDICAL LITERATURE; MEDULLOBLASTOMA; MICROBIOLOGY; MOUTH SQUAMOUS CELL CARCINOMA; MYCOSIS; NASOPHARYNX CARCINOMA; NONHUMAN; PARASITOSIS; POLYOMA VIRUS; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TOXOPLASMOSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS INFECTION;

EID: 84873046599     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-7     Document Type: Review

References (88)

1. GLOBOCAN, 2008 http://globocan.iarc.fr/factsheets/populations/factsheet. asp?uno=900#BOTH
2. The 2007 WHO classification of tumours of the central nervous system. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P, Acta Neuropathol 2007 114 2 97 109 10.1007/s00401-007-0243-4 17618441 (Pubitemid 47103521)
3. Disability in Patients With Head and Neck Cancer. Taylor JC, Terrell JE, Ronis DL, et al. Arch Otolaryngol Head Neck Surg 2004 130 6 764 769 10.1001/archotol.130.6.764 15210560 (Pubitemid 38725053)
4. Future of the TNM classification and staging system in head and neck cancer. Takes RP, Rinaldo A, Silver CE, Piccirillo JF, Haigentz M Jr, Suárez C, Van der Poorten V, Hermans R, Rodrigo JP, Devaney KO, Ferlito A, Head Neck 2010 32 12 1693 1711 10.1002/hed.21361 20191627
5. New TNM staging criteria for head and neck tumors. O'Sullivan B, Shah J, Semin Surg Oncol 2003 21 1 30 42 10.1002/ssu.10019 12923914 (Pubitemid 37127472)
6. Streptococcus anginosus in head and neck squamous cell carcinoma: implication in carcinogenesis. Tateda M, Shiga K, Saijo S, Sone M, Hori T, Yokoyama J, et al. Int J Mol Med 2000 6 699 703 11078831
7. Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Vittecoq M, Elguero E, Lafferty KD, Roche B, Brodeur J, Gauthier-Clerc M, et al. Infect Genet Evol 2012 12 496 498 10.1016/j.meegid.2012.01.013 22285308
8. Human cytomegalovirus infection alters PC3 prostate carcinoma cell adhesion to endothelial cells and extracellular matrix. Blaheta RA, Weich E, Marian D, Bereiter-Hahn J, Jones J, Jonas D, et al. Neoplasia 2006 8 807 816 10.1593/neo.06379 17032497 (Pubitemid 44564836)
9. [Viral cancerogenesis: current point of view]. Alibek K, Sevko AL, Olishevskii SV, Klimenko T, Lik Sprava 2007 5-6 3 25 23373384
10. An update on Epstein-Barr virus and nasopharyngeal carcinogenesis. Perez-Ordonez B, Head Neck Pathol 2007 1 141 145 10.1007/s12105-007-0020-7 20614265
11. Papillomavirus type 16 E6/E7 and human telomerase reverse transcriptase in esophageal cell immortalization and early transformation. Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, et al. Cancer Lett 2007 245 184 194 10.1016/j.canlet.2006.01.005 16488074 (Pubitemid 44970513)
12. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Farwell DG, Shera KA, Koop JI, Bonnet GA, Matthews CP, Reuther GW, et al. Am J Pathol 2000 156 1537 1547 10.1016/S0002-9440(10)65025-0 10793065 (Pubitemid 30646693)
13. Infections as a major preventable cause of human cancer. Kuper H, Adami HO, Trichopoulos D, J Intern Med 2000 248 171 183 10.1046/j.1365-2796.2000. 00742.x 10971784 (Pubitemid 33702479)
14. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Soroceanu L, Matlaf L, Bezrookove V, Harkins L, Martinez R, Greene M, et al. Cancer Res 2011 71 6643 6653 10.1158/0008-5472.CAN-11-0744 21900396
15. The detection of CMV pp 65 and IE1 in glioblastoma multiforme. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C, J Neurooncol 2011 103 231 238 10.1007/s11060-010-0383-6 20820869
16. Human cytomegalovirus infection and expression in human malignant glioma. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Cancer Res 2002 62 3347 3350 12067971 (Pubitemid 34651375)
17. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. Prins RM, Cloughesy TF, Liau LM, N Engl J Med 2008 359 539 541 10.1056/NEJMc0804818 18669440
18. Is cytomegalovirus a therapeutic target in glioblastoma? Sampson JH, Mitchell DA, Clin Cancer Res 2011 17 4619 4621 10.1158/1078-0432.CCR-11-0992 21632859
19. Detection of human cytomegalovirus in different histological types of gliomas. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R, Acta Neuropathol 2008 116 79 86 10.1007/s00401-008-0359-1 18351367
20. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Neuro Oncol 2008 10 10 18 10.1215/15228517-2007-035 17951512 (Pubitemid 351250896)
21. No consistent relationship ofglioblastoma incidence and cytomegalovirus seropositivity in whites, blacks, and Hispanics. Lehrer S, Green S, Ramanathan L, Rosenzweig K, Labombardi V, Anticancer Res 2012 32 3 1113 1115 22399642
22. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. J Clin Invest 2011 121 4043 4055 10.1172/JCI57147 21946257
23. Infectious agents and cancer: criteria for a causal relation. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, et al. Semin Cancer Biol 2004 14 453 471 10.1016/j.semcancer.2004.06.009 15489139 (Pubitemid 39360994)
24. SV40-positive brain tumor in scientist with risk of laboratory exposure to the virus. Arrington AS, Moore MS, Butel JS, Oncogene 2004 23 2231 2235 10.1038/sj.onc.1207341 14676832 (Pubitemid 38482538)
25. Transforming functions of Simian Virus 40. Saenz-Robles MT, Sullivan CS, Pipas JM, Oncogene 2001 20 7899 7907 10.1038/sj.onc.1204936 11753672 (Pubitemid 33135316)
26. Oncogenic transformation by BK virus and association with human tumors. Tognon M, Corallini A, Martini F, et al. Oncogene 2003 22 5192 5200 10.1038/sj.onc.1206550 12910256 (Pubitemid 37059600)
27. Human polyomavirus BK (BKV) and neuroblastoma: mechanisms of oncogenic action and possible strategy for novel treatment. Jorgensen GE, Johnsen JI, Ponthan F, Kogner P, Flaegstad T, Traavik T, Med Pediatr Oncol 2000 35 593 596 10.1002/1096-911X(20001201)35:6<593::AID-MPO22>3.0.CO;2-I 11107125
28. The human polyomavirus BK: Potential role in cancer. Fioriti D, Videtta M, Mischitelli M, Degener AM, Russo G, Giordano A, et al. J Cell Physiol 2005 204 402 406 10.1002/jcp.20300 15690396 (Pubitemid 40934633)
29. Neurocysticercosis and oncogenesis. Del Brutto OH, Dolezal M, Castillo PR, Garcia HH, Arch Med Res 2000 31 151 155 10.1016/S0188-4409(00)00049-7 10880719 (Pubitemid 30392350)
30. Epidemiology of primary brain tumors: current concepts and review of the literature. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS, Neuro Oncol 2002 4 278 299 12356358
31. Incidence of adult brain cancers is higher in countries where the protozoan parasite Toxoplasma gondii is common. Thomas F, Lafferty KD, Brodeur J, Elguero E, Gauthier-Clerc M, Misse D, Biol Lett 2012 8 101 103 10.1098/rsbl.2011.0588 21795265
32. Relationship of central nervous system neoplasms to Toxoplasma gondii infection. Schuman LM, Choi NW, Gullen WH, Am J Public Health Nations Health 1967 57 848 856 10.2105/AJPH.57.5.848 6067209
33. Tumours of the brain and presence of antibodies to Toxoplasma gondii. Ryan P, Hurley SF, Johnson AM, Salzberg M, Lee MW, North JB, et al. Int J Epidemiol 1993 22 412 419 10.1093/ije/22.3.412 8359956 (Pubitemid 23208937)
34. Mycoplasma infections and different human carcinomas. Huang S, Li JY, Wu J, Meng L, Shou CC, World J Gastroenterol 2001 7 266 269 11819772 (Pubitemid 32377482)
35. Mycoplasma pulmonis and lymphoma in a methanol bioassay. Schoeb TR, McConnell EE, Vet Pathol 2011 48 903 905 10.1177/0300985811404713 21508330
36. Mycoplasma pneumoniae: Innocent Bystander or a True Cause of Central Nervous System Disease? Bitnun A, Richardson SE, Curr Infect Dis Rep 2010 12 282 290 10.1007/s11908-010-0105-4 21308543
37. Medulloblastoma and Brucellosis-Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. Zhang B, Izadjoo M, Horkayne-Szakaly I, Morrison A, Wear DJ, J Cancer 2011 2 136 141 21475718
38. Epstein-Barr virus in head and neck cancer assessed by quantitative polymerase chain reaction. Goldenberg D, Benoit NE, Begum S, Westra WH, Cohen Y, Koch WM, Sidransky D, Califano JA, Laryngoscope 2004 114 6 1027 1031 10.1097/00005537-200406000-00013 15179207 (Pubitemid 38736511)
39. Nasopharyngeal carcinoma. Brennan B, Orphanet J Rare Dis 2006 1 23 10.1186/1750-1172-1-23 16800883
40. A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin-cisplatin and radiotherapy. Pendjer I, Krejovic B, Vucicevic S, Eur Arch Otorhinolaryngol 1997 254 Suppl 1 127 S129 9065646
41. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Ozyar E, Ayhan A, Korcum AF, Atahan IL, Cancer Invest 2004 22 483 491 10.1081/CNV-200026386 15565804 (Pubitemid 39506867)
42. HPV-associated head and neck cancer: a virus-related cancer epidemic. Marur S, D'Souza G, Westra WH, Forastiere AA, Lancet Oncol 2010 11 781 789 10.1016/S1470-2045(10)70017-6 20451455
43. HPV & head and neck cancer: a descriptive update. Goon PK, Stanley MA, Ebmeyer J, Steinstrasser L, Upile T, Jerjes W, et al. Head Neck Oncol 2009 1 36 10.1186/1758-3284-1-36 19828033
44. Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas. Wolff HA, Rodel RM, Gunawan B, Overbeck T, Herrmann MK, Hennies S, et al. J Cancer Res Clin Oncol 2010 136 89 97 10.1007/s00432-009-0640-2 19618214
45. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretrociral therapy. Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M, Lancet 2006 367 1495 1502 10.1016/S0140-6736(06)68649-2 16679162
46. Human retroviruses: their role in cancer. Blattner WA, Proc Assoc Am Physicians 1999 111 6 563 572 10.1046/j.1525-1381.1999.99210.x 10591085
47. Otolaryngological manifestations of HIV/AIDS: A Review. Lasisi OA, Ann Ibadan Postgrad Med 2005 3 1 33 39
48. Structure and function of latency-associated nuclear antigen. Verma SC, Lan K, Robertson E, Curr Top Microbiol Immunol 2007 312 101 136 10.1007/978-3-540-34344-8-4 17089795 (Pubitemid 47400345)
49. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S, Lancet Infect Dis 2002 2 6 344 352 10.1016/S1473-3099(02)00288-8 12144897 (Pubitemid 34595974)
50. AIDS-related malignancies. Boshoff C, Weiss R, Nat Rev Cancer 2002 2 5 373 382 10.1038/nrc797 12044013 (Pubitemid 37328950)
51. KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Biberfeld P, Infect Agent Canc 2007 2 4 10.1186/1750-9378-2-4
52. Streptococcus anginosus infection in oral cancer and its infection route. Sasaki M, Yamaura C, Ohara-Nemoto Y, Tajika S, Kodama Y, Ohya T, et al. Oral Dis 2005 11 151 156 10.1111/j.1601-0825.2005.01051.x 15888105 (Pubitemid 40776325)
53. Presence of Streptococcus infection in extra-oropharyngeal head and neck squamous cell carcinoma and its implication in carcinogenesis. Shiga K, Tateda M, Saijo S, Hori T, Sato I, Tateno H, et al. Oncol Rep 2001 8 245 248 11182034 (Pubitemid 33758072)
54. Different frequencies of Streptococcus anginosus infection in oral cancer and esophageal cancer. Morita E, Narikiyo M, Yano A, Nishimura E, Igaki H, Sasaki H, et al. Cancer Sci 2003 94 492 496 10.1111/j.1349-7006.2003.tb01471.x 12824872 (Pubitemid 36849711)
55. The role of bacteria in oral cancer. Chocolatewala N, Chaturvedi P, Desale R, Indian J Med Paediatr Oncol 2010 31 126 131 10.4103/0971-5851.76195 21584217
56. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM, J Transl Med 2005 3 27 10.1186/1479-5876-3-27 15987522 (Pubitemid 41522080)
57. Consensus on the role of human cytomegalovirus in glioblastoma. Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS, Neuro Oncol 2012 14 3 246 255 10.1093/neuonc/nor227 22319219
58. Recent advances in the molecular understanding of glioblastoma. Bleeker FE, Molenaar RJ, Leenstra S, J Neurooncol 2012 108 1 11 27 10.1007/s11060-011- 0793-0 22270850
59. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Maussang D, Langemeijer E, Fitzsimons CP, Stigter-van WM, Dijkman R, Borg MK, et al. Cancer Res 2009 69 2861 2869 10.1158/0008-5472.CAN-08-2487 19318580
60. Stability and function of JC virus large T antigen and T' proteins are altered by mutation of their phosphorylated threonine 125 residues. Tyagarajan SK, Frisque RJ, J Virol 2006 80 2083 2091 10.1128/JVI.80.5.2083-2091.2006 16474116 (Pubitemid 43271515)
61. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. White MK, Khalili K, Virology 2004 324 1 16 10.1016/j.virol.2004.03.025 15183048 (Pubitemid 38737394)
62. JC virus: an oncogenic virus in animals and humans? Maginnis MS, Atwood WJ, Semin Cancer Biol 2009 19 261 269 10.1016/j.semcancer.2009.02.013 19505654
63. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K, et al. J Neuroinflammation 2008 5 48 10.1186/1742-2094-5-48 18947414
64. Depressive effect of a Taenia solium cysticercus factor on cultured human lymphocytes stimulated with phytohaemagglutinin. Molinari JL, Tato P, Reynoso OA, Cazares JM, Ann Trop Med Parasitol 1990 84 205 208 2222021 (Pubitemid 20323508)
65. Association between malaria incidence and all cancer mortality in fifty U.S. States and the District of Columbia. Lehrer S, Anticancer Res 2010 30 1371 1373 20530455
66. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8, cytokines, growth factors and HIV in pathogenesis of Kaposi's sarcoma. Biberfeld P, Ensoli B, Sturzl M, Schulz TF, Curr Opin Infect Dis 1998 11 2 97 105 10.1097/00001432-199804000-00002 17033372 (Pubitemid 28163820)
67. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Dalgleish AG, O'Byrne KJ, Adv Cancer Res 2002 84 231 276 11883529 (Pubitemid 34188199)
68. Some aspects of the pathogenesis of HIV-1-associated Kaposi's sarcoma. Gallo RC, J Natl Cancer Inst Monogr 1998 23 55 57 9709304
69. HIV-1: fifteen proteins and an RNA. Frankel AD, Young JA, Annu Rev Biochem 1998 67 1 25 10.1146/annurev.biochem.67.1.1 9759480 (Pubitemid 28411121)
70. Regulation of HIV-1 gene expression by the transactivator protein Tat. Gaynor RB, Curr Top Microbiol Immunol 1995 193 51 77 10.1007/978-3-642-78929-8-3 7648878
71. Kaposi's sarcoma: the role of HHV-8 and HIV-1 in pathogenesis. Foreman KE, Expert Rev Mol Med 2001 2001 1 17 14987376
72. Chlamydia pneumoniae infection and risk of lung cancer. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, Vaughan TL, Cancer Epidemiol Biomarkers Prev 2004 13 10 1624 1630 15466979 (Pubitemid 39331884)
73. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. Koyi H, Brandén E, Gnarpe J, Gnarpe H, Steen B, APMIS 2001 109 9 572 580 10.1034/j.1600-0463.2001.d01-177.x 11878709 (Pubitemid 32929731)
74. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. Kocazeybek B, J Med Microbiol 2003 52 Pt 8 721 726 12867569 (Pubitemid 36981483)
75. Inflammation and cancer. Coussens LM, Werb Z, Nature 2002 420 6917 860 867 10.1038/nature01322 12490959 (Pubitemid 36019639)
76. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Nougayrède JP, Taieb F, De Rycke J, Oswald E, Trends Microbiol 2005 13 3 103 110 10.1016/j.tim.2005.01.002 15737728 (Pubitemid 40311892)
77. Opinion: Bacterial toxins and cancer-a case to answer? Lax AJ, Nat Rev Microbiol 2005 3 4 343 349 10.1038/nrmicro1130 15806096 (Pubitemid 40443727)
78. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW, Onkologie 2008 31 691 693 19060508
79. Candida albicans as a promoter of oral mucosal neoplasia. O'Grady JF, Reade PC, Carcinogenesis 1992 13 5 783 786 10.1093/carcin/13.5.783 1586990
80. Agents Classified by the IARC Monographs, Volumes 1-106 2012 http://monographs.iarc.fr/ENG/Classification/ClassificationsGroupOrder.pdf 11789462
81. Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix§ssup§®§esup§ Schwarz TF, Adv Ther 2009 26 983 998 10.1007/s12325-009-0079-5 20024678
82. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Wick DA, Webb JR, Vaccine 2011 29 7857 7866 10.1016/j.vaccine.2011.07.090 21816200
83. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. Zhao L, Liu B, Ren J, Feng J, Pang Z, Gao J, et al. Virol J 2011 8 302 10.1186/1743-422X-8-302 21672263
84. Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus. Melief CJ, Cancer J 2011 17 5 300 301 10.1097/PPO. 0b013e318235e0fe 21952279
85. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, et al. J Immunother 2012 35 159 168 10.1097/CJI. 0b013e318247642f 22306904
86. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. Yoshizaki T, Wakisaka N, Kondo S, Murono S, Shimizu Y, Nakashima M, et al. J Med Virol 2008 80 879 882 10.1002/jmv.21165 18360900 (Pubitemid 351500036)
87. Epstein-Barr virus and human herpesvirus type 8 infections of the central nervous system. Volpi A, Herpes 2004 11 Suppl 2 120A 127A 15319099
88. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Hanel M, Fiedler F, Thorns C, Onkologie 2001 24 491 494 10.1159/000055132 11694778 (Pubitemid 33033414)